Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Passiglia, Francesco; Novello, Silvia

doi:10.21037/atm.2018.12.25

Cited by 2 publications

(2 citation statements)

References 20 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pembrolizumab is not only studied in NSCLC but also in SCLC. Studies have shown that metastatic SCLC after platinum-based chemotherapy and at least one other therapy has an objective response rate, when treated with pembrolizumab, of 18.7% and a median OS of 9.1 months [30].…”

Section: Efficacymentioning

confidence: 99%

Immune Checkpoint Inhibitors in Lung Cancer

Chen¹,

Jian²,

Yuan-dong³

2022

HSET

View full text Add to dashboard Cite

With the fast increase in morbidity and mortality, lung cancer has become one of the greatest threats to physical health in some countries. Immune checkpoint inhibitors (ICIs) have a significant influence on the treatment landscape of lung cancer, including non-small cell lung cancer (NSCLC). This review highlights the most important ICIs used in lung cancer at present, anti-CTLA-4 and PD-1/L1. The application status, efficacy, shortcomings and prospect of each drug, including Ipilimumab (CTLA-4), Nivolumab, Pembrolizumab, and Durvalumab (PD-1/L1), are listed to show the drug indication in the current market. By comparing different drugs, the direction of ICI drug development can be more precise, which can have an important influence on choosing drugs for lung cancer treatment.

show abstract

Section: Efficacymentioning

confidence: 99%

Immune Checkpoint Inhibitors in Lung Cancer

Chen¹,

Jian²,

Yuan-dong³

2022

HSET

View full text Add to dashboard Cite

show abstract

“…Disappointingly, ICIs have not shown a significant advantage in the maintenance setting. In a phase II study, pembrolizumab 200 mg IV every 3 weeks was given as maintenance therapy after first-line platinum doublet chemotherapy in 45 patients (19). Median PFS was 1.4 months and therefore did not improve median PFS compared with the historical data.…”

Section: Review Articlementioning

confidence: 99%

What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?

Nesbit¹,

Leal²,

Kruser³

2019

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Small cell lung cancer has been a difficult disease to treat with poor survival and few significant improvements in outcomes in the last three decades. Most recently the addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) resulted in improved overall survival and progression-free survival compared to chemotherapy alone. Recent randomized studies examining both consolidative thoracic radiotherapy and prophylactic cranial irradiation (PCI) in ES-SCLC have impacted the utilization of these interventions. The approval of immune checkpoint inhibitors (ICIs) to platinum/etoposide chemotherapy for the treatment of ES-SCLC in the front-line setting may also further impact the role of radiotherapy in this disease. In this article, we review the current evidence supporting thoracic radiotherapy in ES-SCLC and discuss the promising therapeutic implications of thoracic radiation in light of the inclusion of ICIs. We also address how the increasing routine use of surveillance brain magnetic resonance imaging (MRI) and ICIs may diminish the use of PCI in ES-SCLC.

show abstract

Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

Cited by 2 publications

References 20 publications

Immune Checkpoint Inhibitors in Lung Cancer

Immune Checkpoint Inhibitors in Lung Cancer

What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?

Contact Info

Product

Resources

About